December 12th, 2022, Tokyo, Japan – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed two novel synthetic peptides, “BMP7 selective inhibitor (product code: PG-005)” and “BMP4 selective inhibitor (product code: PG-006)”, which selectively bind and inhibit BMP7 and BMP4 respectively. We started marketing this product on December 8th, 2022. [Read more…]
Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human Pluripotent Stem Cells
MINNEAPOLIS, Nov. 17, 2022 — Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and transISRIB (CEPT) cocktail. This publication outlines a robust and scalable workflow for cloning human pluripotent stem cells (hPSCs) that maximizes the viability of the cells using the Namocell Single Cell Dispenser. [Read more…]
Ronawk To Be Platinum Sponsor of TERMIS-Americas In Boston April 11-14, 2023
Olathe, KS – Ronawk, the biotech and biofabrication company powered by the Bio-Block™ platform, today shared that they have agreed to be the platinum sponsor of TERMIS-Americas in Boston April 11-14, 2023.
TERMIS is focused on “Advancing Tissue Engineering & Regenerative Medicine Worldwide To Generate Knowledge With A View To Improving Patient Outcomes Globally”. The event itself is focused on “Tissue Engineering Strategies For Human Health and Longevity” which aligns perfectly with the goal of the Ronawk team to accelerate research for next-generation therapies. [Read more…]
OmniSpirant Limited and EVerZom Announce the Launch of INSPIRE; an EU Project funded under the Horizon Europe research and innovation programme to develop a ground-breaking inhaled gene therapy for the treatment of lung cancer based on extracellular vesicles
Galway, 25th November 2022 –OmniSpirant Limited and EVerZom are delighted and honoured to announce the launch of INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant in collaboration with our European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy, are already actively working on the project deliverables, and recently met in Galway, Ireland for the official kick-off meeting (see the picture below taken on the 28th October 2022). [Read more…]
Avectas, CCRM and OmniaBio Expand Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® Technology
DUBLIN, Ireland and TORONTO, Canada, Nov. 29, 2022 — Avectas, a cell engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO that enables the development of cell therapies and associated technologies for clinical and commercial manufacture, have announced an expansion of their collaboration, to enable the development of gene-edited induced pluripotent stem cells (iPSCs) using Avectas’ non-viral cell engineering platform, SOLUPORE®. [Read more…]
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 96
- Next Page »